Xintela newsletter January 2022

Dear shareholders,

I would like to wish you all a Happy New Year, briefly summarize the past year for Xintela and its subsidiary Targinta, and focus on some important upcoming events that we are looking forward to in 2022.

It has been a fantastic and eventful year for our companies with, among other things, an approved GMP facility for the production of our stem cell products, preparations for two clinical studies with XSTEM, recruitment of several key people in GMP production and clinical development, and also successful preclinical studies for Targinta, which has now chosen its first antibody-based candidate drug TARG10. Our patent portfolio has also developed very positively with the approval of patents that protect our drug development in both stem cell therapy and antibody-based cancer therapy and at the same time give us a strong position towards competitors.

In the stem cell business, we have conducted four different preclinical studies during the past year, all of which were very successful and showed positive effects of our selected stem cells for the treatment of both osteoarthritis, difficult-to-heal wounds and the lung complication ARDS (Acute Respiratory Disease Syndrome). The results have given us important information about the mechanisms of action of the stem cells and strong support for continued clinical development in these areas. This has led to Xintela now entering a clinical phase and starting its first clinical studies with XSTEM. We will start treatment of patients with knee osteoarthritis in the beginning of this year in Australia and in the middle of the year start a clinical study in Linköping on patients with difficult-to-heal leg ulcers. The goal is to show safety and preliminary efficacy and we expect to have the first readouts by the end of this year. XSTEM is the first integrin α10-selected stem cell product to enter clinical trials and, based on our preclinical results, we have high hopes to see regenerative effects in both osteoarthritis of the knee and in difficult-to-heal leg ulcers.

Our positive preclinical studies on horses, with the stem cell product EQSTEM, have also led us to start a collaboration with the Danish veterinary company ScanVet with the goal of jointly bringing EQSTEM to the market for the treatment of osteoarthritis in horses. Since our approved stem cell product patent protects both XSTEM and EQSTEM for all therapeutic use, we can look forward to developing stem cell-based treatments in a number of medical areas going forward.

In the oncology program, which is run by our subsidiary Targinta, we have during the year worked intensively to develop human antibodies and evaluate these in preclinical cancer models. The goal is to identify effective drug candidates for the treatment of aggressive cancer including the brain tumor glioblastoma and triple-negative breast cancer. The work has led to selection of our first candidate drug, TARG10, which has an inhibitory effect on both tumor growth and metastasis in cancer models. Work is also ongoing to evaluate antibodies armed with powerful toxins, so-called antibody-drug conjugates (ADCs), in order to soon be able to select the next candidate drug. The success of the research gives Targinta a really good start when the company is to be spun off at the beginning of the year and further developed as an independent company. We have convened a general meeting on January 17 to get our shareholders’ decision to implement the planned spin-off with the goal of listing Targinta shortly thereafter. In addition, Targinta has been strengthened with a very experienced management and board and has the best conditions to take quick steps towards partnerships and clinical studies.

We at Xintela and Targinta are now looking forward to a really exciting 2022.

With best regards,
Evy Lundgren-Åkerlund, CEO
Xintela AB


Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

January 18, 2022
Xintela granted 4.8 million SEK from Vinnova
December 13, 2021
Xintela and ScanVet Animal Health A/S sign Letter of Intent
November 19, 2021
Xintela AB Interim report January – September 2021
November 4, 2021
Xintela AB announces update on status and strategy for Xintela and Targinta
October 29, 2021
Xintela AB announces the appointment of a new board of directors in Targinta AB.
October 27, 2021
Xintela taking EQSTEM, a stem cell product for horses, towards the market.
October 15, 2021
The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10.
September 30, 2021
Xintela to expand clinical development of stem cell product XSTEM
August 27, 2021
Xintela Half-year Report 2021-01-01 - 2021-06-30
July 16, 2021
Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO)
July 1, 2021
Xintela incorporates subsidiary
June 17, 2021
Xintela has completed a directed new share issue raising proceeds of approximately SEK 28 million
June 16, 2021
Xintela intends to carry out a directed share issue through an accelerated book building procedure
May 21, 2021
Xintela’s GMP facility approved for manufacturing of cell therapy products
May 20, 2021
Xintela to develop stem cell therapy for difficult-to-heal wounds
May 18, 2021
Xintela's stem cell product XSTEM repairs cartilage damage in preclinical model
May 4, 2021
Targinta recruits Per Norlén as CEO
April 12, 2021
Xintela GMP inspection for manufacturing license completed
April 6, 2021
Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
March 19, 2021
Xintela gets tissue establishment license
March 17, 2021
Xintela gets patent grant in Europe for XSTEM stem cell product
March 12, 2021
Xintela publishes results from glioblastoma antibody study
February 26, 2021
Year-end report 1 Jan 2020 – 31 Dec 2020
January 7, 2021
Xintela receives Notice of Allowance from USPTO for the treatment of brain tumors
December 21, 2020
Xintela submits manufacturing license application
December 14, 2020
Xintela recruits Jeffrey Abbey to Targinta
December 4, 2020
Arbitral award rendered in favour of Xintela in dispute with former underwriters
December 3, 2020
Xintela Board recommends Maarten de Château as new Board member
November 27, 2020
Xintela publishes interim report for the third quarter of 2020
November 12, 2020
Xintela Board recommends Lars Hedbys as new Board member
October 30, 2020
Status report of Xintela published by BioStock
October 29, 2020
Xintela receives ‘intention to grant’ decision from European Patent Office for stem cell product XSTEM
October 28, 2020
Xintela applies for tissue establishment license
October 26, 2020
Xintela's stem cells show promising results in preclinical ARDS study
August 19, 2020
Xintela strengthens management team
July 29, 2020
Xintela receives Notice of Allowance from USPTO
June 23, 2020
Granted preliminary approval from the European Patent Office for the treatment of brain tumors
June 17, 2020
Xintela develops treatment for aggressive breast cancer
May 8, 2020
Xintela granted 1 million SEK from Vinnova
March 27, 2020
Xintela has been granted 2 million SEK from Vinnova in the call for "Innovation projects in small and medium-sized companies"
February 3, 2020
Positive preclinical results from equine study
December 11, 2019
Positive preclinical results in Xintela’s glioblastoma project
November 29, 2019
Interim report 1 JAN 2019-30 SEP 2019
April 26, 2019
The Board of Xintela AB (publ) announces that Peter Edman has been nominated for election to the Board at the annual general meeting
April 26, 2019
The results of the company's glioblastoma study have now been published in the renowned international scientific journal Cancers.
April 16, 2019
Xintela appoints Sven Kili as Chief Operating Officer
February 27, 2019
Xintela publishes its Year-end Report for 2018
February 15, 2019
Xintela publishes results from stem cell study
January 8, 2019
Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers
October 25, 2018
The parties intend to jointly develop an ADC therapeutic product with a first focus on glioblastoma
August 29, 2018
Xintela has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB.
August 29, 2018
Sven Kili extends his commitment to Xintela as Chief Medical Officer
August 21, 2018
Xintela announces an update on the company's development programs
August 9, 2018
Xintela today announced that the company's international patent application has been published
July 9, 2018
Xintela signs Letter of Intent with CO.DON
June 28, 2018
Xintela receives MUMS-status for the treatment of osteoarthritis in horses
April 26, 2018
Xintela's GMP facility is completed and being prepared for production and clinical trials
April 17, 2018
Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio
March 20, 2018
Xintela prepares for a possible spin-out of its oncology business into a separate company
February 22, 2018
Xintela publishes the Year-end Report for 2017-01-01 - 2017-12-31
December 29, 2017
Xintela licenses human antibody technology for cancer therapy
December 19, 2017
Xintela to collaborate with Japanese CellSeed Inc.
November 13, 2017
Xintela raises 17 million SEK in debt and equity
October 17, 2017
Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons.
September 11, 2017
Xintela building own GMP-facility for stem cell production
July 17, 2017
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
June 22, 2017
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
May 22, 2017
Xintela signs Memorandum of Understanding with the leading European cell therapy company, CO.DON
May 9, 2017
Xintela: Keld Sondergaard nominated as new board member
March 21, 2017
Xintela announces today that Thomas Areschoug has been recruited to the business development team......
February 8, 2017
(In Swedish) Xintela: Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO1
January 20, 2017
Xintela reports positive preclinical results in cancer project
January 4, 2017
Xintela´s stem cells show positive treatment effects on cartilage damage in horse study
December 22, 2016
Xintela reports positive results from completed horse study
September 12, 2016
Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016.
August 22, 2016
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation.
June 23, 2016
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor
June 1, 2016
Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs
April 25, 2016
Xintela initiates a study on the treatment of cartilage damage in horses in the USA.
March 16, 2016
Xintela's press releases are currently only published in Swedish. Please contact us if you have further questions.
January 10, 2022
We would like to wish you all a Happy New Year and briefly summarize the past year for Xintela and its subsidiary Targinta
August 18, 2021
We are now closing in on our next major milestone: initiating clinical trials with the stem cell product XSTEM.
January 26, 2021
Xintela Newsletter December 2020
November 9, 2020
Xintela is targeting several important milestones in the remainder of 2020 and 2021
January 13, 2020
Newsletter December 2019
July 30, 2019
Newsletter July 2019
May 8, 2019
Projects in both regenerative medicine and oncology are making progress and developing very positively.
January 14, 2019
Xintela has worked intensively to connect the company with potential partners and international investors.
January 14, 2019
The following presentation summarises the status of Xintela’s various activities and overall plans for the coming year.
July 17, 2018
Strong first six months for Xintela
March 27, 2018
Large-scale stem cell production paves the way for GMP-certified production
January 5, 2018
Pre-Christmas breakthrough promises an exciting 2018
September 28, 2017
‍Strategic decisions that builds significant value
July 19, 2017
Focusing on Stem Cell Production and Preparations for Clinical Trials
May 16, 2017
On the 21st March 2017, Xintela reported that it was strengthening its Business Development team...
April 5, 2017
A word from the CEO
February 15, 2017
The subscription period for shares supported by warrants has started
December 29, 2016
A Year of Significant Progress
December 14, 2016
Glioblastoma—Xintela's Focus in the Cancer Arena
November 8, 2016
Starting the Autumn with an increased focus on Xintela’s commercial development
October 19, 2016
Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
August 11, 2016
Confidence in the future with a strong organisation
August 11, 2016
Welcome to Xintela's newsletter
January 10, 2022
BIO Partnering at JPM
10-14 Januari 2022
February 27, 2020

BioStock interview with Xintela's CMO and board member Sven Kili.

August 30, 2018

BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.

February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 15, 2016

Investor presentation from Lund - Jan 27

January 14, 2016

Interview with Xintelas CEO

October 12, 2021
BioStock: Professor Folke Sjöberg about XSTEM for treatment of venous leg ulcers.
November 9, 2020
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in regarding that its stem cells are safe for use in horses
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
December 10, 2021
Edison Group has published a research update on Xintela.
July 14, 2021
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
A status report of the Xintela has been published by Biostock
April 12, 2018
Read the full analysis here